Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive (DBCOND0031249)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04188405	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia	Decitabine Ponatinib Venetoclax	treatment	2	active_not_recruiting
NCT03576547	Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	Dexamethasone Ponatinib Rituximab Venetoclax	treatment	1 / 2	completed
NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	Fludarabine	treatment	1	suspended
NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	Aldesleukin Busulfan Fludarabine Natural Killer Cell	treatment	1 / 2	completed
NCT04681105	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	treatment	1	active_not_recruiting
NCT03246906	Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation	Cyclophosphamide Cyclosporine Mycophenolate mofetil Sirolimus	treatment	2	active_not_recruiting
NCT01904136	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	Cyclophosphamide Fludarabine Mechlorethamine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT01746836	Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib	Ponatinib	treatment	2	recruiting
NCT02861417	Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant	Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus Thiotepa Tromethamine	treatment	2	active_not_recruiting
NCT03807063	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant	Rimiducid Rivogenlecleucel	treatment	1	withdrawn
NCT02381548	Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	Adavosertib Belinostat	treatment	1	terminated
NCT00789776	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT02730195	Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia	Pioglitazone Tyrosine	treatment	2	terminated
NCT01527045	Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Atorvastatin Cyclosporine Fludarabine Mycophenolate mofetil	prevention	2	completed
NCT02311998	Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML	Bosutinib Inotuzumab ozogamicin	treatment	1 / 2	completed
NCT01822509	Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	Ipilimumab Nivolumab	treatment	1	completed
NCT02220985	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	Cyclophosphamide Fludarabine Methopterin Methotrexate Mycophenolate mofetil Tacrolimus Thiotepa Tromethamine	treatment	2	active_not_recruiting
NCT02728700	Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT	Mycophenolate mofetil Sirolimus	prevention	1	terminated
NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Flotetuzumab	treatment	2	withdrawn
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT03630991	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Edetate calcium disodium anhydrous Edetic acid Succimer	treatment	1	recruiting
NCT00105001	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Sirolimus Tacrolimus	treatment	2	completed
NCT04526795	Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia	Cytarabine Fludarabine Pegcrisantaspase	treatment	1	active_not_recruiting
NCT02115295	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Cladribine Cytarabine Gilteritinib Idarubicin Midostaurin Venetoclax	treatment	2	recruiting